The drug works differently from stimulants, but the two-week study was designed to test safety, and its symptom results were not compared with placebo.
An experimental pill that targets orexin, a brain chemical best known for keeping people awake, was followed by improvements in ADHD symptoms among adults in a small, early-stage study, drugmaker Alkermes announced on September 21. The company's phase 1b results announcement describes the findings as the first clinical evidence of the effects of an orexin-activating drug in ADHD.
